Abstract
The landscape of breast cancer management has been revolutionized by advancements in molecular diagnostics, yet accessibility and cost remain significant barriers for many patients. Limited-resource settings often face significant challenges in accessing expensive molecular tests, which can impact timely diagnosis and treatment decisions. The Magee equations present a practical, cost-effective solution that can bridge this gap, ensuring that patients, regardless of their financial or geographic limitations, receive appropriate and timely treatment. Originally developed at the University of Pittsburgh Medical Center, these equations offer a reliable alternative for estimating recurrence scores without the prohibitive costs associated with genomic assays.